Brief: Beyondspring Presents New Clinical Evidence Of Plinabulin Protection Of Granulocyte-Monocyte Progenitor Stem Cells For The Prevention Of Chemotherapy-Induced Neutropenia At The ESMO Congress 2022
13/09/2022 12:04
Sept 13 (Reuters) - Beyondspring Inc BYSI.O :
* BEYONDSPRING PRESENTS NEW CLINICAL EVIDENCE OF PLINABULIN
PROTECTION OF GRANULOCYTE-MONOCYTE PROGENITOR STEM CELLS FOR THE
PREVENTION OF CHEMOTHERAPY-INDUCED NEUTROPENIA AT THE ESMO
CONGRESS 2022
Source text for Eikon: ID:nGNX4Y0nrD
Further company coverage: BYSI.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Beyondspring
See all newsBrief: Beyondspring Inc Entered Into Open Market Sale Agreement Under Which Co May Offer And Sell Up To 9.2 Million Ordinary Shares
Brief: Beyondspring Announces FDA Fast Track Designation For Plinabulin In Post-Ici Non-Squamous Nsclc And Strategic Transaction To Advance Global Phase 3 Dublin-4 Trial Toward Planned Interim Analysis
NASDAQ RESUMED AT 12:26 PM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 12:21 PM
Brief: Beyondspring Announces Leadership Transition To Deliver Focused Execution On Its Confirmatory Dublin-4 Program And Long-Term Value